Terms: = Prostate cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
379 results:
1. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract] [Full Text] [Related]
2. Targeted Ultrasound Nanobubbles Therapy for prostate cancer via Immuno-Sonodynamic Effect.
Huang X; Chen Y; Zhong F; Gui B; Hu Y; Guo Y; Deng Q; Zhou Q
Int J Nanomedicine; 2024; 19():2793-2806. PubMed ID: 38525011
[TBL] [Abstract] [Full Text] [Related]
3. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
4. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
[TBL] [Abstract] [Full Text] [Related]
5. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
6. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Tsai AK; Kagalwalla S; Langer J; Le-Kumar T; Le-Kumar V; Antonarakis ES
Expert Opin Biol Ther; 2024; 24(1-2):51-62. PubMed ID: 38284349
[TBL] [Abstract] [Full Text] [Related]
7. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD; Guan X; Rishipathak D; Rapaport AS; Shehata HM; Banchereau R; Yuen K; Varfolomeev E; Hu R; Han CJ; Li H; Liang Y; Vucic D; Wang L; Zhu J; Yu H; Herbst RH; Hajaj E; Kiner E; Bamias A; De Santis M; Davis ID; Arranz JÁ; Kikuchi E; Bernhard S; Williams P; Lee C; Mellman I; Sanjabi S; Johnston R; Black PC; Grande E; Mariathasan S
Cell Rep Med; 2024 Feb; 5(2):101393. PubMed ID: 38280376
[TBL] [Abstract] [Full Text] [Related]
8. Tumor-associated macrophages and pd-l1 in prostate cancer: a possible key to unlocking immunotherapy efficacy.
Wang J; Wu W; Yuan T; Wang L; Zang L; Liu Q; Wang L; Huo X; Huo B; Tang Y; Wang H; Zhao Z
Aging (Albany NY); 2024 Jan; 16(1):445-465. PubMed ID: 38189834
[TBL] [Abstract] [Full Text] [Related]
9. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract] [Full Text] [Related]
10. Development of a ferroptosis-based molecular markers for predicting RFS in prostate cancer patients.
Chen J; Zhang L; Luo Y; Tan C; Hu H; Jiang Y; Xi N; Zeng Q; Peng H
Sci Rep; 2023 Dec; 13(1):22804. PubMed ID: 38129557
[TBL] [Abstract] [Full Text] [Related]
11. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
[TBL] [Abstract] [Full Text] [Related]
12. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
[TBL] [Abstract] [Full Text] [Related]
13. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma.
Nishiyama H; Yonese J; Kawahara T; Matsumoto R; Miyake H; Matsubara N; Uemura H; Eto M; Azuma H; Obara W; Terai A; Fukasawa S; Suekane S
Mol Cancer Ther; 2024 Apr; 23(4):532-540. PubMed ID: 38060587
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis.
Noori M; Azizi S; Mahjoubfar A; Abbasi Varaki F; Fayyaz F; Mousavian AH; Bashash D; Kardoust Parizi M; Kasaeian A
Front Immunol; 2023; 14():1181051. PubMed ID: 38022569
[TBL] [Abstract] [Full Text] [Related]
15. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and pd-l1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (pd-l1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant prostate cancer: A Systematic Review and Meta-analysis.
Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
[TBL] [Abstract] [Full Text] [Related]
17. A tumor-associated heparan sulfate-related glycosaminoglycan promotes the generation of functional regulatory T cells.
Martín-Cruz L; Viñuela M; Kalograiaki I; Angelina A; Oquist-Phillips P; Real-Arévalo I; Cañada FJ; Tudela JI; Moltó L; Moreno-Sierra J; Subiza JL; Palomares O
Cell Mol Immunol; 2023 Dec; 20(12):1499-1512. PubMed ID: 37990034
[TBL] [Abstract] [Full Text] [Related]
18. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
19. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
[Next]
